TORI 104 Pre-Surgical Dasatinib
Phase 2
Withdrawn
- Conditions
- Breast Cancer
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- AHS Cancer Control Alberta
- Registration Number
- NCT01410708
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences
- Conditions
- Prostate Cancer
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 20
- Registration Number
- NCT01355185
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
Phase 2
Withdrawn
- Conditions
- Colorectal CarcinomaNeoplasms, ColorectalMetastasisColorectal CancerColorectal Tumors
- Interventions
- Dietary Supplement: Glutamine
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Registration Number
- NCT01157039
Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients
Phase 1
- Conditions
- Colorectal CarcinomaColorectal CancerNeoplasms, Colorectal
- Interventions
- Other: (supplement) Calcium and Magnesium
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 15
- Registration Number
- NCT01157052
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Feasibility Study to Compare the Benefits of Endoscopic Tumor Clip Placement and 3T-MRI Simulation for Accurate Target Volume Definition for Rectal Cancer Patients Undergoing Pre-operative Chemoradiation
Not Applicable
Completed
- Conditions
- Rectal Cancer
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT01133340
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
Phase 2
Completed
- Conditions
- Gastrointestinal NeoplasmGastric Adenocarcinoma
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 47
- Registration Number
- NCT01129310
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Tomosynthesis in Screening Mammography
Not Applicable
Completed
- Conditions
- Breast Density >25%
- Interventions
- Procedure: TomosynthesisProcedure: 2D Mammogram
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 500
- Registration Number
- NCT01086241
- Locations
- 🇨🇦
Alberta Screen Test, Edmonton, Alberta, Canada
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
Phase 1
Terminated
- Conditions
- Brain CancerSolid TumorCancerLymphoma
- Interventions
- Biological: 18F-FLT
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 94
- Registration Number
- NCT01065805
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 11
- Registration Number
- NCT01034787
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)
Completed
- Conditions
- Heart FailureRenal Cell CarcinomaHypertensionCardiotoxicity
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 42
- Registration Number
- NCT01014065
- Locations
- 🇨🇦
University of Alberta/ Cross Cancer Institute, Edmonton, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath